All In Biotech

Drug Trial Radar · NCT04314375

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Sep 29, 2023

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.

Conditions

  • Ulcerative Colitis

Interventions

  • Low Dose BudesonideDrug

    3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.

  • High Dose BudesonideDrug

    6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.

  • PlaceboDrug

    Matching placebo once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the proportion of subjects who achieve clinical remission at Day 56, defined as a total Mayo score of ≤ 1 with subscores of 0 for both rectal bleeding and stool frequency, and a subscore of ≤ 1 for endoscopy.Time frame: 56 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Health Site 008

    Garden Grove, California · Recruiting

  • Bausch Health Site 003

    Indianapolis, Indiana · Recruiting

  • Bausch Health Site 006

    The Bronx, New York · Recruiting

  • Bausch Health Site 010

    Greenville, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.